As of November 6, 2026, Enzo Biochem Inc has Schedule 13D or 13G filings on record, none whose latest reports a stake of 5% or more. 3 filings are on record since July 1, 2025 (Schedule 13G/A, November 14, 2025).
Sell to companies like Enzo Biochem Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Beryl Capital Management LLC · Percent: 0% · SCHEDULE 13G/A
- · Holder: Radoff Bradley Louis · Percent: 0% · SCHEDULE 13D/A
- · Holder: Beryl Capital Management LLC · Percent: 9.7% · SCHEDULE 13G
Enzo Biochem Inc has 3 Schedule 13D or 13G filings on record since 2025-07-01. No holder's latest filing reports 5% or more. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Beryl Capital Management LLC | 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| 0% | 0 | SCHEDULE 13D/A, 2025-08-22 | 2025-08-20 |
Holding shares or following this stake? See who's behind Enzo Biochem Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Enzo Biochem Inc and the records around it.
Companies that share a holder
- Beryl Capital Management LLC also filed stake reports on 4 other companies: Vigil Neuroscience, Inc. (Nov 2025), Y-mAbs Therapeutics, Inc. (Nov 2025)
- Radoff Family Foundation also filed stake reports on 11 other companies: Identiv, Inc. (Nov 2026), HARTE HANKS INC (Aug 2026), REGIONAL HEALTH PROPERTIES, INC (Aug 2026)
Watch Enzo Biochem Inc
Get an email when Enzo Biochem Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Enzo Biochem Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Enzo Biochem Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Enzo Biochem Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
Radoff Bradley Louis
Item 4 is hereby amended to add the following: On June 23, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Bethpage Parent, Inc., a Delaware corporation ("Parent"), and Bethpage Merger Sub, Inc., a New York corporation and a wholly owned subsidiary of Parent ("Merger Sub"). On August 20, 2025, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") effective as of the effective time of the Merger (the "Effective Time"), with the Issuer continuing as the surviving corporation of the Merger and a wholly owned subsidiary of Parent. At the Effective Time, each Share that was issued and outstanding immediately prior to the Effective Time, subject to certain customary exceptions specified in the Merger Agreement, was automatically converted into the right to receive $0.70 in cash, without interest (the "Merger Consideration")and subject to applicable withholding taxes. In addition, pursuant to the Merger Agreement, at the Effective Time, (i) each Issuer restricted stock unit ("RSU") that was outstanding as of immediately prior to the Effective Time and was either (A) held by a member of the Issuer's board of directors (whether vested or unvested) or (B) vested in accordance with its terms but not yet settled as of the Effective Time (each, a "Vested RSU") was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-08-22; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-01 | Beryl Capital Management LLC | 9.7% | SCHEDULE 13G |
| 2025-08-22 | Radoff Bradley Louis | 0% | SCHEDULE 13D/A |
| 2025-11-14 | Beryl Capital Management LLC | 0% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Enzo Biochem Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.